Summary
Global Markets Direct’s, ‘Tuberculosis - Pipeline Review, H1 2016’, provides an overview of the Tuberculosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Tuberculosis
- The report reviews pipeline therapeutics for Tuberculosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Tuberculosis therapeutics and enlists all their major and minor projects
- The report assesses Tuberculosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Tuberculosis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Tuberculosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tuberculosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Abera Bioscience AB
Achillion Pharmaceuticals, Inc.
Alvogen Korea Co., Ltd.
Anacor Pharmaceuticals, Inc.
Archivel Farma S.L.
AstraZeneca Plc
Bayer AG
BioDiem Ltd
BioLingus AG
Biomar Microbial Technologies
Bioversys AG
Celgene Corporation
Cellceutix Corporation
Chongqing Zhifei Biological Products Co., Ltd.
Dafra Pharma International Ltd.
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
Eli Lilly and Company
Ensol Biosciences Inc.
EpiVax, Inc.
FIT Biotech Oy
GangaGen Inc.
GlaxoSmithKline Plc
Globeimmune, Inc.
Hager Biosciences, LLC
Hsiri Therapeutics, LLC
Imaxio SA
Immunitor, Inc.
ImmunoBiology Limited
Immunovaccine, Inc.
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Lipotek Pty Ltd.
Matinas BioPharma Holdings, Inc.
Microbion Corporation
Microbiotix, Inc.
NEARMEDIC PLUS, Ltd
Novartis AG
NovoBiotic Pharmaceuticals, LLC
Otsuka Holdings Co., Ltd.
Polymun Scientific Immunbiologische Forschung GmbH
Prokarium Limited
QureTech Bio AB
Recce Limited
Rodos BioTarget GmbH
Sanofi
Sanofi Pasteur SA
Sarepta Therapeutics, Inc.
SEEK Group
Sequella, Inc.
Shionogi & Co., Ltd.
Sphaera Pharma Pvt. Ltd.
Spring Bank Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
TetraLogic Pharmaceuticals
Theravectys SA
Tomegavax, Inc.
Transgene SA
TVAX Biomedical, Inc.
Univalue Valorizacion, S.L.
Vaccibody AS
Vakzine Projekt Management GmbH
Vaxil Bio Therapeutics Ltd.
Vertex Pharmaceuticals Incorporated
Vichem Chemie Research Ltd.
'
Table of Contents
Table of Contents 2
Introduction 6
Tuberculosis Overview 7
Therapeutics Development 8
Tuberculosis - Therapeutics under Development by Companies 10
Tuberculosis - Therapeutics under Investigation by Universities/Institutes 15
Tuberculosis - Pipeline Products Glance 18
Tuberculosis - Products under Development by Companies 22
Tuberculosis - Products under Investigation by Universities/Institutes 29
Tuberculosis - Companies Involved in Therapeutics Development 34
Tuberculosis - Therapeutics Assessment 99
Drug Profiles 111
Tuberculosis - Recent Pipeline Updates 337
Tuberculosis - Dormant Projects 356
Tuberculosis - Discontinued Products 366
Tuberculosis - Product Development Milestones 367
Appendix 378
List of Tables
Number of Products under Development for Tuberculosis, H1 2016 28
Number of Products under Development for Tuberculosis - Comparative Analysis, H1 2016 29
Number of Products under Development by Companies, H1 2016 30
Number of Products under Development by Companies, H1 2016 (Contd..1) 31
Number of Products under Development by Companies, H1 2016 (Contd..2) 32
Number of Products under Development by Companies, H1 2016 (Contd..3) 33
Number of Products under Development by Companies, H1 2016 (Contd..4) 34
Number of Products under Investigation by Universities/Institutes, H1 2016 35
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 36
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 37
Comparative Analysis by Late Stage Development, H1 2016 38
Comparative Analysis by Clinical Stage Development, H1 2016 39
Comparative Analysis by Early Stage Development, H1 2016 40
Comparative Analysis by Unknown Stage Development, H1 2016 41
Products under Development by Companies, H1 2016 42
Products under Development by Companies, H1 2016 (Contd..1) 43
Products under Development by Companies, H1 2016 (Contd..2) 44
Products under Development by Companies, H1 2016 (Contd..3) 45
Products under Development by Companies, H1 2016 (Contd..4) 46
Products under Development by Companies, H1 2016 (Contd..5) 47
Products under Development by Companies, H1 2016 (Contd..6) 48
Products under Investigation by Universities/Institutes, H1 2016 49
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 50
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 51
Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 52
Products under Investigation by Universities/Institutes, H1 2016 (Contd..4) 53
Tuberculosis - Pipeline by Abera Bioscience AB, H1 2016 54
Tuberculosis - Pipeline by Achillion Pharmaceuticals, Inc., H1 2016 55
Tuberculosis - Pipeline by Alvogen Korea Co., Ltd., H1 2016 56
Tuberculosis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 57
Tuberculosis - Pipeline by Archivel Farma S.L., H1 2016 58
Tuberculosis - Pipeline by AstraZeneca Plc, H1 2016 59
Tuberculosis - Pipeline by Bayer AG, H1 2016 60
Tuberculosis - Pipeline by BioDiem Ltd, H1 2016 61
Tuberculosis - Pipeline by BioLingus AG, H1 2016 62
Tuberculosis - Pipeline by Biomar Microbial Technologies, H1 2016 63
Tuberculosis - Pipeline by Bioversys AG, H1 2016 64
Tuberculosis - Pipeline by Celgene Corporation, H1 2016 65
Tuberculosis - Pipeline by Cellceutix Corporation, H1 2016 66
Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2016 67
Tuberculosis - Pipeline by Dafra Pharma International Ltd., H1 2016 68
Tuberculosis - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 69
Tuberculosis - Pipeline by Eisai Co., Ltd., H1 2016 70
Tuberculosis - Pipeline by Eli Lilly and Company, H1 2016 71
Tuberculosis - Pipeline by Ensol Biosciences Inc., H1 2016 72
Tuberculosis - Pipeline by EpiVax, Inc., H1 2016 73
Tuberculosis - Pipeline by FIT Biotech Oy, H1 2016 74
Tuberculosis - Pipeline by GangaGen Inc., H1 2016 75
Tuberculosis - Pipeline by GlaxoSmithKline Plc, H1 2016 76
Tuberculosis - Pipeline by Globeimmune, Inc., H1 2016 77
Tuberculosis - Pipeline by Hager Biosciences, LLC, H1 2016 78
Tuberculosis - Pipeline by Hsiri Therapeutics, LLC, H1 2016 79
Tuberculosis - Pipeline by Imaxio SA, H1 2016 80
Tuberculosis - Pipeline by Immunitor, Inc., H1 2016 81
Tuberculosis - Pipeline by ImmunoBiology Limited, H1 2016 82
Tuberculosis - Pipeline by Immunovaccine, Inc., H1 2016 83
Tuberculosis - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 84
Tuberculosis - Pipeline by Johnson & Johnson, H1 2016 85
Tuberculosis - Pipeline by Lipotek Pty Ltd., H1 2016 86
Tuberculosis - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016 87
Tuberculosis - Pipeline by Microbion Corporation, H1 2016 88
Tuberculosis - Pipeline by Microbiotix, Inc., H1 2016 89
Tuberculosis - Pipeline by NEARMEDIC PLUS, Ltd, H1 2016 90
Tuberculosis - Pipeline by Novartis AG, H1 2016 91
Tuberculosis - Pipeline by NovoBiotic Pharmaceuticals, LLC, H1 2016 92
Tuberculosis - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 93
Tuberculosis - Pipeline by Polymun Scientific Immunbiologische Forschung GmbH, H1 2016 94
Tuberculosis - Pipeline by Prokarium Limited, H1 2016 95
Tuberculosis - Pipeline by QureTech Bio AB, H1 2016 96
Tuberculosis - Pipeline by Recce Limited, H1 2016 97
Tuberculosis - Pipeline by Rodos BioTarget GmbH, H1 2016 98
Tuberculosis - Pipeline by Sanofi, H1 2016 99
Tuberculosis - Pipeline by Sanofi Pasteur SA, H1 2016 100
Tuberculosis - Pipeline by Sarepta Therapeutics, Inc., H1 2016 101
Tuberculosis - Pipeline by SEEK Group, H1 2016 102
Tuberculosis - Pipeline by Sequella, Inc., H1 2016 103
Tuberculosis - Pipeline by Shionogi & Co., Ltd., H1 2016 104
Tuberculosis - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016 105
Tuberculosis - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016 106
Tuberculosis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 107
Tuberculosis - Pipeline by TetraLogic Pharmaceuticals, H1 2016 108
Tuberculosis - Pipeline by Theravectys SA, H1 2016 109
Tuberculosis - Pipeline by Tomegavax, Inc., H1 2016 110
Tuberculosis - Pipeline by Transgene SA, H1 2016 111
Tuberculosis - Pipeline by TVAX Biomedical, Inc., H1 2016 112
Tuberculosis - Pipeline by Univalue Valorizacion, S.L., H1 2016 113
Tuberculosis - Pipeline by Vaccibody AS, H1 2016 114
Tuberculosis - Pipeline by Vakzine Projekt Management GmbH, H1 2016 115
Tuberculosis - Pipeline by Vaxil Bio Therapeutics Ltd., H1 2016 116
Tuberculosis - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 117
Tuberculosis - Pipeline by Vichem Chemie Research Ltd., H1 2016 118
Assessment by Monotherapy Products, H1 2016 119
Assessment by Combination Products, H1 2016 120
Number of Products by Stage and Target, H1 2016 122
Number of Products by Stage and Mechanism of Action, H1 2016 125
Number of Products by Stage and Route of Administration, H1 2016 128
Number of Products by Stage and Molecule Type, H1 2016 130
Tuberculosis Therapeutics - Recent Pipeline Updates, H1 2016 357
Tuberculosis - Dormant Projects, H1 2016 376
Tuberculosis - Dormant Projects (Contd..1), H1 2016 377
Tuberculosis - Dormant Projects (Contd..2), H1 2016 378
Tuberculosis - Dormant Projects (Contd..3), H1 2016 379
Tuberculosis - Dormant Projects (Contd..4), H1 2016 380
Tuberculosis - Dormant Projects (Contd..5), H1 2016 381
Tuberculosis - Dormant Projects (Contd..6), H1 2016 382
Tuberculosis - Dormant Projects (Contd..7), H1 2016 383
Tuberculosis - Dormant Projects (Contd..8), H1 2016 384
Tuberculosis - Dormant Projects (Contd..9), H1 2016 385
Tuberculosis - Discontinued Products, H1 2016 386
List of Figures
Number of Products under Development for Tuberculosis, H1 2016 28
Number of Products under Development for Tuberculosis - Comparative Analysis, H1 2016 29
Number of Products under Development by Companies, H1 2016 30
Number of Products under Investigation by Universities/Institutes, H1 2016 35
Comparative Analysis by Late Stage Development, H1 2016 38
Comparative Analysis by Clinical Stage Development, H1 2016 39
Comparative Analysis by Early Stage Products, H1 2016 40
Assessment by Monotherapy Products, H1 2016 119
Assessment by Combination Products, H1 2016 120
Number of Products by Top 10 Targets, H1 2016 121
Number of Products by Stage and Top 10 Targets, H1 2016 121
Number of Products by Top 10 Mechanism of Actions, H1 2016 124
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 124
Number of Products by Top 10 Routes of Administration, H1 2016 127
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 127
Number of Products by Top 10 Molecule Types, H1 2016 129
Number of Products by Stage and Top 10 Molecule Types, H1 2016 129
